Sarepta Therapeutics Inc., of Cambridge, Mass., established a long-term manufacturing agreement with Paragon Bioservices Inc., of Baltimore, to manufacture its microdystrophin Duchenne muscular dystrophy gene therapy and future gene therapy programs targeting diseases such as limb-girdle muscular dystrophy. Terms of the agreement weren't disclosed.